Important: The POPLINE website will retire on September 1, 2019. Click here to read about the transition.

Your search found 2 Results

  1. 1

    Initiative for Vaccine Research. Task Force on Clinical Trials of Dengue Vaccines, 14 November 2002.

    World Health Organization [WHO]. Vaccines and Biologicals Department. Initiative for Vaccine Research. Task Force on Clinical Trials of Dengue Vaccines

    Geneva, Switzerland, WHO, 2002. 12 p. (VAB/IVR/VIR2002.03.1)

    The second meeting of the WHO Task Force on Clinical Trials of Dengue Vaccines was held on 14 November 2002 in Denver, Colorado, USA. The Task Force was established to accelerate the development, evaluation, and introduction of urgently needed dengue vaccine candidates. The main objective of the Task Force is to continue to analyze results on safety, immunogenicity, and efficacy of currently available vaccine candidates in clinical trials and to provide scientific advice on the next steps to be taken, giving special attention to vaccine safety. The meeting reviewed the progress in clinical trials of four live attenuated vaccine candidates. The task force recommended specific activities in support of future development and clinical studies and identified the role of WHO in this process. The meeting was co-sponsored by the Pediatric Dengue Vaccine Initiative. (excerpt)
    Add to my documents.
  2. 2

    DengueNet Implementation in the Americas. Report of a WHO / PAHO / CDC Meeting, San Juan, Puerto Rico, 9-11 July 2002.

    World Health Organization [WHO]. Department of Communicable Disease Surveillance and Response; Pan American Health Organization [PAHO]. Division of Communicable Diseases Prevention and Control; United States. Centers for Disease Control and Prevention [CDC]

    Geneva, Switzerland, World Health Organization [WHO], Department of Communicable Disease Surveillance and Response, 2003. [45] p. (Global Health Security. Epidemic Alert and Response; WHO/CDS/CSR/GAR/2003.8; PAHO/HCP/HCT/V/230/03)

    The geographical spread of both the mosquito vectors and the viruses has led to the global resurgence of epidemic dengue fever/dengue haemorrhagic fever (dengue/DHF) in the past 25 years with the development of hyperendemicity in many urban centres of the tropics. Globally, 2.5 billion people live in areas where dengue viruses can be transmitted. The number of countries with epidemic DHF is continuing to rise. A pandemic in 1998, in which 1.2 million cases of dengue fever and DHF were reported from 56 countries, was unprecedented. Data for 2001-2002 indicate a situation of comparable magnitude. It is estimated that 50 million dengue infections occur each year with 500 000 cases of DHF and at least 12 000 deaths, mainly among children. Only a small proportion of cases are reported to WHO. The challenge for national and international health agencies is to reverse the trend of increased epidemic dengue activity and increased incidence of DHF. Epidemiological and laboratory-based surveillance is required to monitor and guide dengue/DHF prevention and control programmes, regardless of whether the form of control used is mosquito control or possible vaccination if an effective and safe vaccine becomes available. The reporting of dengue/DHF however is not standardized. Epidemiological and laboratory data are often collected by different institutions and reported in different formats, resulting in delay and comparability problems at regional and international levels. To address these problems WHO has created DengueNet, an Internet-based central data management system to collect and analyse standardized epidemiological and virological data for the global surveillance of dengue/DHF and to provide national and international public health authorities with epidemiological and virological indicators by place and time that can guide public health prevention and control actions. (excerpt)
    Add to my documents.